CELG Celgene Corporation

By Michael Dabaie

Celgene Corp. (CELG) said the U.S. Food and Drug Administration (FDA) approved Revlimid in combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.

Celgene said this is the first FDA-approved combination treatment regimen for patients with these indolent forms of non-Hodgkin's lymphoma that doesn't include chemotherapy.

Approval was based on a Phase 3 study which showed the combination significantly improved median progression-free survival versus rituximab monotherapy, the company said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

May 28, 2019 12:55 ET (16:55 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.